Catalent (CTLT)
(Delayed Data from NYSE)
$55.80 USD
-0.15 (-0.27%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $55.80 0.00 (0.00%) 7:58 PM ET
5-Strong Sell of 5 5
D Value C Growth B Momentum C VGM
Company Summary
Somerset, NJ-based Catalent, Inc. is a renowned global provider of advanced delivery technologies as well as development and manufacturing solutions for drugs; protein, cell, and gene therapy biologics; and consumer health products. Catalent operates through two arms following the change in its organizational structure. This includes a shift from four reporting segments to two — newly formed Pharma and Consumer Health (PCH) segment (consolidating the prior Softgel & Oral Technologies, Oral & Specialty Delivery and Clinical Supply Services segments) and Biologics. Each represents roughly half of Catalent’s total revenue.
...
Company Summary
Somerset, NJ-based Catalent, Inc. is a renowned global provider of advanced delivery technologies as well as development and manufacturing solutions for drugs; protein, cell, and gene therapy biologics; and consumer health products. Catalent operates through two arms following the change in its organizational structure. This includes a shift from four reporting segments to two — newly formed Pharma and Consumer Health (PCH) segment (consolidating the prior Softgel & Oral Technologies, Oral & Specialty Delivery and Clinical Supply Services segments) and Biologics. Each represents roughly half of Catalent’s total revenue.
Biologics (46.4% of aggregate revenues in FY 2023, down 21% at constant exchange rate or CER from FY 2022): The segment provides biologic cell-line, cell therapy and viral vector gene therapy development and manufacturing; formulation, development, and manufacturing of parenteral dose forms, including prefilled syringes, vials, and cartridges; and analytical development and testing services for large molecules. Further, the growing biologics offering includes cell-line development based on Catalent’s advanced and patented GPEx technology and the GPEx Boost.
PCH (53.6%, up 4%): The PCH segment encompasses the offerings of three of the company's prior reportable segments — Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services — and comprises Catalent’s capabilities for complex oral solids, softgel formulations, Zydis fast-dissolve technologies, and gummy, soft chew, and lozenge dosage forms; formulation, development, and manufacturing platforms for oral, nasal, inhaled, and topical dose forms; and clinical trial development and supply services.
General Information
Catalent, Inc
14 SCHOOLHOUSE ROAD
SOMERSET, NJ 08873
Phone: 732-537-6200
Fax: 732-537-6480
Email: investors@catalent.com
Industry | Medical - Drugs |
Sector | Medical |
Fiscal Year End | June |
Last Reported Quarter | 3/31/2024 |
Exp Earnings Date | 6/10/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | 0.24 |
Current Year EPS Consensus Estimate | 0.55 |
Estimated Long-Term EPS Growth Rate | 33.10 |
Exp Earnings Date | 6/10/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 55.95 |
52 Week High | 60.20 |
52 Week Low | 31.45 |
Beta | 1.20 |
20 Day Moving Average | 1,542,774.00 |
Target Price Consensus | 60.07 |
4 Week | -0.94 |
12 Week | 8.35 |
YTD | 24.53 |
4 Week | 2.52 |
12 Week | 3.52 |
YTD | 17.12 |
Shares Outstanding (millions) | 180.97 |
Market Capitalization (millions) | 10,125.51 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | 0.00 |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | 101.73 |
Trailing 12 Months | NA |
PEG Ratio | 3.07 |
vs. Previous Year | -153.23% |
vs. Previous Quarter | -65.00% |
vs. Previous Year | -10.18% |
vs. Previous Quarter | 5.09% |
Price/Book | 2.74 |
Price/Cash Flow | 17.25 |
Price / Sales | 2.46 |
3/31/24 | NA |
12/31/23 | -2.43 |
9/30/23 | 1.55 |
3/31/24 | NA |
12/31/23 | -0.98 |
9/30/23 | 0.65 |
3/31/24 | NA |
12/31/23 | 2.48 |
9/30/23 | 1.70 |
3/31/24 | NA |
12/31/23 | 1.73 |
9/30/23 | 1.19 |
3/31/24 | NA |
12/31/23 | -2.48 |
9/30/23 | 1.65 |
3/31/24 | NA |
12/31/23 | -29.91 |
9/30/23 | -22.36 |
3/31/24 | NA |
12/31/23 | -34.91 |
9/30/23 | -26.96 |
3/31/24 | NA |
12/31/23 | 20.41 |
9/30/23 | 21.31 |
3/31/24 | NA |
12/31/23 | 4.35 |
9/30/23 | 4.17 |
3/31/24 | NA |
12/31/23 | 1.34 |
9/30/23 | 1.13 |
3/31/24 | NA |
12/31/23 | 57.36 |
9/30/23 | 52.95 |